Disease Landscape and Forecast Insights

Non-alcoholic steatohepatitis (NASH) is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of…

The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2021-2031 period. In China, even though systemic targeted drugs for hepatocellular carcinoma…

Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizable portion of the Chinese population every year. With the introduction of proteasome…

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the…

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the…

Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence…

Migraine presents a major public health burden in China, leading to impaired quality of life, widespread health loss, and loss of productivity for a sizeable population. Owing to migraine’s…

Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity…

The approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of Roche’s Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then, biosimilars of…

Atopic dermatitis is a common skin disease that significantly affects quality of life. For many years, atopic dermatitis treatment in China included only conventional topical/systemic agents and no…